Medetomidine Is Not Xylazine. That's the Problem.

Substance Spotlight — Novel & Emerging · Day 150 · May 30, 2026

---

In October 2025, the Knox County Regional Forensic Center in East Tennessee started seeing overdose deaths that didn’t fit the pattern. Patients were arriving with fentanyl in their toxicology reports alongside a second compound the lab couldn’t immediately identify. By January 2026, the Center for Forensic Science Research and Education had confirmed 25 fatal cases across East Tennessee. By April, the novel compound — cychlorphine, also called N-propionitrile chlorphine — had spread across eight Tennessee counties and turned up in Chicago drug seizures. By May 12, the DEA was sending a national public safety advisory about it to every law enforcement and public health agency in the country.

The DEA advisory covered four substances, not one. Cychlorphine. Medetomidine. Nitazenes. Xylazine. All four are now appearing in street fentanyl — often in combination, often without the knowledge of the person buying what they believe to be a pressed oxycodone or a bag of heroin. All four require different response protocols than fentanyl alone. None of them can be reliably detected by the standard harm reduction tools most programs have been distributing for the past three years.

This is not a story about the future of the drug supply. It is a description of what the drug supply is right now.

Medetomidine: the xylazine replacement that arrived without warning

Harm reduction workers in Philadelphia and Baltimore spent most of 2022 and 2023 learning to recognize xylazine — the veterinary sedative that causes the characteristic skin wounds, the deep sedation, the partial naloxone resistance. The training happened under pressure. People were dying from tranq wounds, from the cardiovascular effects of alpha-2 agonist suppression, from naloxone-resistant episodes where responders used their full supply and the person stayed down.

Now xylazine is being displaced by something worse.

Medetomidine is also an alpha-2 adrenergic agonist — the same drug class as xylazine, but 100 to 200 times more potent. The same mechanism that makes xylazine non-responsive to naloxone makes medetomidine non-responsive to naloxone. The CDC’s National Forensic Laboratory Information System recorded 247 medetomidine-positive drug supply samples in 2023. By 2024, that number was 2,616. By 2025, it was 8,233 — a 950 percent increase in two years. In Massachusetts, where the state has one of the most sophisticated drug supply surveillance systems in the country, medetomidine has now appeared in every county. Xylazine prevalence dropped from 35 percent of samples in 2024 to 20 percent in 2025. Medetomidine filled the gap.

The clinical picture is more severe than xylazine. Medetomidine’s longer half-life means sedation can last hours, not minutes. The withdrawal syndrome — which xylazine also produces — is, according to clinicians at the MATTERS Network and practitioners publishing in the Annals of Emergency Medicine, severe enough to require intensive care management in some cases. Standard urine drug screens do not detect medetomidine. There is no antagonist equivalent to naloxone in the clinical toolkit. Treatment is supportive: maintain airway, treat hypotension and bradycardia, wait.

That is not a harm reduction protocol. That is an ICU protocol. And most people who encounter medetomidine in street fentanyl encounter it on a sidewalk, not in a trauma bay.

What naloxone can and cannot do

Naloxone is a mu-opioid receptor antagonist. It works by binding to opioid receptors and displacing fentanyl, heroin, oxycodone, and other opioids from those sites. It does not affect alpha-2 adrenergic receptors. When xylazine or medetomidine is present alongside fentanyl, naloxone reverses the opioid component but leaves the alpha-2 component intact. The person may regain the ability to breathe — which is what stops fentanyl deaths — but will remain profoundly sedated, cardiovascularly compromised, and unable to protect their own airway.

This means the standard bystander protocol — administer naloxone, call 911, put in recovery position — now applies with a critical caveat: if the person doesn’t respond to two doses of naloxone within 3-5 minutes, assume an alpha-2 agonist adulterant is present. Maintain an open airway. Do not leave. The breathing may normalize without the consciousness returning.

The DEA advisory recommends administering naloxone regardless because the fentanyl component remains life-threatening and reversible. That guidance is correct. It is also incomplete. The full protocol requires treating the alpha-2 component as a separate and potentially more prolonged emergency — one that currently has no pharmacological intervention outside of a hospital setting.

The DEA advisory recommends administering naloxone regardless because the fentanyl component remains life-threatening and reversible.

Harm reduction programs that are still training bystanders on single-dose naloxone protocols are not wrong, but they are behind the curve. The national shift to intranasal high-dose formulations (8mg) and the American Journal of Emergency Medicine finding that single-step devices achieve 85 percent success rates versus 20 percent for multi-step kits are steps in the right direction. But the bigger need is updated training that names medetomidine explicitly, teaches bystanders to recognize the non-responsive sedation pattern, and prepares them to stay on scene rather than assuming the intervention is complete.

Nitazenes and cychlorphine: the opioid threat is also evolving

Medetomidine and xylazine are non-opioid adulterants. The opioid part of the drug supply is also changing.

The DEA has identified 22 unique nitazene compounds since 2020; 21 are now Schedule I. The nitazene class is structurally unrelated to fentanyl but acts on the same mu-opioid receptors. The potency range is wide — some nitazenes are less potent than fentanyl on a microgram basis, others are estimated at 10 to 43 times more potent. Houston documented a 57 percent increase in nitazene-related deaths between November 2024 and February 2025. The DEA confirmed detections in 47 states as of Q1 2026.

The clinical challenge: standard fentanyl immunoassay test strips do not reliably detect most nitazene variants. A person using a fentanyl test strip and getting a negative result may have a nitazene in their supply instead. This is not a failure of the test strip — the strip was designed for fentanyl. It is a failure of the assumption that fentanyl is what’s in the pill. As of April 2026, SAMHSA removed federal funding for fentanyl test strips entirely. It has not provided an alternative.

Cychlorphine, the East Tennessee compound, is a synthetic opioid from a different chemical class than both fentanyl and nitazenes — a chlorphine derivative that researchers at CFSRE are still characterizing. It may require multiple naloxone doses for reversal. Its duration of action compared to fentanyl is not yet fully established. Its appearance in Chicago suggests it is no longer a regional phenomenon. It has no DEA scheduling history because it was unknown to the DEA until last fall.

The Nitazene Control Act (H.R. 5032), currently before the 119th Congress, would create a scheduling mechanism for novel nitazene analogs as they emerge. No companion bill has advanced in the Senate. In the meantime, each new compound that enters the supply exists in a regulatory gray zone — not yet scheduled, not yet on any standard drug screen, not yet accounted for in any treatment protocol.

What treatment and harm reduction need to do now

The practical implications for anyone working in addiction medicine or harm reduction in 2026 are not theoretical:

For harm reduction programs: Update training materials to name medetomidine specifically. Retire materials that describe xylazine as the primary alpha-2 threat — medetomidine has already displaced it in multiple markets. Train bystanders to stay on scene past the first naloxone dose and maintain airway support. Advocate for fentanyl test strip access to continue through non-federal funding where federal funding has been cut.

For emergency departments: The MATTERS Network and AAFP issued updated clinical guidance in 2026 on medetomidine management. The core recommendation: treat alpha-2 agonist symptoms with supportive care and cardiovascular monitoring regardless of naloxone response. Anticipate prolonged sedation. Request drug supply context from responders.

For treatment providers: Update intake and patient education materials to describe the current drug supply accurately. The person entering treatment in Arizona in May 2026 may have been using a drug that contained fentanyl, medetomidine, and a nitazene simultaneously without knowing any of those names. Their withdrawal profile, their overdose history, and their clinical needs reflect that complexity.

For policymakers: The SAMHSA test strip ban removed the primary supply-detection tool at the exact moment the supply became most dangerous. The 2026 National Drug Control Strategy itself says test strips “should be legal and not considered drug paraphernalia.” The contradiction between that statement and the April 24 SAMHSA guidance has not been resolved. Resolving it is urgent, and the mechanism exists to do so — a clarifying guidance letter or emergency exemption from CMS would restore funding for state and local harm reduction programs within weeks.

The drug supply in 2026 is not fentanyl with a side problem. It is a multi-compound delivery system that standard protocols were not designed to address. The name matters. Calling it “tranq” when it’s medetomidine, calling it fentanyl when it’s a nitazene, means people get the wrong information. The wrong information costs lives that the right information would have saved.

---

For information on naloxone access, test strip programs, and harm reduction resources in Arizona, visit Rize Recovery or the Arizona Harm Reduction Coalition.